Zoetis Inc. $ZTS Shares Sold by US Bancorp DE

US Bancorp DE decreased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 96,134 shares of the company's stock after selling 8,068 shares during the period. US Bancorp DE's holdings in Zoetis were worth $14,993,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. grew its position in Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares during the last quarter. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp grew its holdings in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after buying an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock valued at $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its position in Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock valued at $725,866,000 after acquiring an additional 312,746 shares during the period. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Argus reiterated a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus lowered shares of Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat, Zoetis presently has an average rating of "Hold" and an average price target of $196.71.

Zoetis Price Performance

ZTS stock opened at $141.05 on Friday. The firm has a 50 day moving average of $149.24 and a 200-day moving average of $154.41. The company has a market cap of $62.51 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 2.26 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis's payout ratio is 34.42%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.